The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …

Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated
worsening of disability, which is assumed to be mainly associated with transient infiltration of …

Cancer heterogeneity, a hallmark enabling clonal survival and therapy resistance, is shaped
by active immune responses. Antigen-specific T cells can control cancer, as revealed …

Clinical development of BTK kinase inhibitors for treating autoimmune diseases has lagged
behind development of these drugs for treating cancers, due in part from concerns over the …

Background Chronic spontaneous urticaria (CSU) is inadequately controlled in many
patients and greatly affects quality of life. Remibrutinib, a highly selective, oral, novel …

Structural analysis of flexible macromolecular systems such as intrinsically disordered or
multidomain proteins with flexible linkers is a difficult task as high-resolution techniques are …

Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase
important in B‐lymphocyte development, differentiation, and signaling. Btk is a member of …

Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in
immunity and is considered an attractive target for treating autoimmune diseases. The use of …

The prototypic non-receptor tyrosine kinase c-Abl is implicated in various cellular processes.
Its oncogenic counterpart, the Bcr–Abl fusion protein, causes certain human leukaemias …

Objective To evaluate fenebrutinib, an oral and highly selective noncovalent inhibitor of
Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arthritis (RA). Methods …